IBIO (iBio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Molly Carr | Chief Medical Officer | A | — | — |
| 2026-05-19 | Elizabeth Stoner | Director | A | — | — |
| 2026-03-27 | Marc Banjak | Chief Legal Officer | Buy | — | — |
| 2026-03-23 | Felipe Duran | Chief Financial Officer | Buy | — | — |
| 2026-03-23 | Martin Brenner | See Remarks | Buy | — | — |
| 2026-01-30 | Martin Brenner | See Remarks | A | — | — |
| 2026-01-30 | Marc Banjak | Chief Legal Officer | A | — | — |
| 2026-01-30 | Felipe Duran | Chief Financial Officer | A | — | — |
| 2025-11-24 | Gary Sender | Director | A | — | — |
| 2025-11-24 | Alexandra Kropotova | Director | A | — | — |
| 2025-11-24 | Evert B. Schimmelpennink | Director | A | — | — |
| 2025-11-24 | Antonio Bernardino Guimaraes Parada | Director | A | — | — |
| 2025-11-24 | William D Clark | Director | A | — | — |
| 2025-11-24 | David Arkowitz | Director | A | — | — |
| 2025-10-22 | Felipe Duran | Chief Financial Officer | A | — | — |
| 2025-10-22 | Marc Banjak | Chief Legal Officer | A | — | — |
| 2025-10-22 | Martin Brenner | See Remarks | A | — | — |
| 2025-02-24 | Martin Brenner | See Remarks | A | — | — |
| 2025-02-24 | Felipe Duran | Chief Financial Officer | A | — | — |
| 2025-02-24 | Marc Banjak | Chief Legal Officer | A | — | — |
| 2025-01-13 | Martin Brenner | See Remarks | Buy | — | — |
| 2025-01-13 | William D Clark | Director | Buy | — | — |
| 2025-01-13 | Gary Sender | Director | Buy | — | — |
| 2025-01-13 | Marc Banjak | Chief Legal Officer | Buy | — | — |
| 2025-01-13 | Felipe Duran | Chief Financial Officer | Buy | — | — |
| 2025-01-13 | David Arkowitz | Director | Buy | — | — |
| 2025-01-13 | Antonio Bernardino Guimaraes Parada | Director | Buy | — | — |
| 2024-12-09 | Antonio Bernardino Guimaraes Parada | Director | A | — | — |
| 2024-11-25 | Alexandra Kropotova | Director | A | — | — |
| 2024-11-25 | Gary Sender | Director | A | — | — |
| 2024-11-25 | David Arkowitz | Director | A | — | — |
| 2024-11-25 | William D Clark | Director | A | — | — |
| 2024-11-25 | Evert B. Schimmelpennink | Director | A | — | — |
| 2024-05-13 | Felipe Duran | Chief Financial Officer | A | — | — |
| 2024-05-13 | Martin Brenner | See Remarks | A | — | — |
| 2024-04-26 | Felipe Duran | Chief Financial Officer | A | — | — |
| 2023-11-03 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-10-05 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-10-03 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-08-30 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-08-24 | Felipe Duran | Chief Financial Officer | A | — | — |
| 2023-08-24 | Martin Brenner | See Remarks | A | — | — |
| 2023-07-28 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-07-13 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-06-27 | Martin Brenner | See Remarks | MIXED | — | — |
| 2023-06-22 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-05-24 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-04-24 | Martin Brenner | See Remarks | Sell | — | — |
| 2023-04-03 | Martin Brenner | See Remarks | A | — | — |
| 2023-04-03 | Felipe Duran | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 183,823 | — |
| — | 10%+ Owner | 71,765 | — |
| — | 10%+ Owner | 63,518 | — |
| — | Chief Financial Officer | 35,974 | — |
| — | See Remarks | 30,652 | — |
| — | Chief Legal Officer | 25,000 | — |
| — | Director | 18,382 | — |
| — | Director | 9,191 | — |
| — | 10%+ Owner | 5,449 | — |
| — | See Remarks | 5,108 | — |
| — | CEO and Executive Chairman | 2,550 | — |
| — | Director | 1,838 | — |
| — | 10%+ Owner | 1,678 | — |
| — | 10%+ Owner | 1,150 | — |
| — | Chief Operating Officer | 544 | — |
| — | Director | 375 | — |
| — | President | 216 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IBIO quote page; the site-wide leaderboard is on the insider transactions hub.